This list contains references from the content that can be linked to their source. For a full set of references and notes please see the PDF or HTML where available.
JacksonRG, StamfordJA, StruninL. The canary is dead.Anaesthesia2003; 58: 911–912.
SchulzKF, GrimesDA. Allocation concealment in randomised trials: defending against deciphering.Lancet2002; 359: 614–618.
ChalmersI. Why transition from alternation to randomisation in clinical trials was made.BMJ1999; 319: 1372.
DaySJ, AltmanDG. Statistical notes; blinding in clinical trials and other studies.BMJ 2000; 321: 504.
TobinJR, ShaferSL, DavisPJ. Pediatric research and scholarship: another Gordian Knot?Anesth Analg2006; 103: 43–48.
KunzR, OxmanAD. The unpredictability paradox: review of empirical comparisons of randomised and non-randomised clinical trials.BMJ1998; 317: 1185–1190.
JulianDG. What is right and what is wrong about evidence-based medicine?J Cardiovasc Electrophysiol2003; 14(9 Suppl): S2–S5.
ManganoDT, TudorIC, DietzelC. Multicentre Study of Perioperative Ischemia Research Group, Ischemia Research and Education Foundation. The risk associated with aprotinin in cardiac surgery.New Engl J Med2006; 354: 353–365.
Kirk-SmithMD, StretchDD. Evidence-based medicine and randomized double-blind clinical trials: a study of flawed implementation.J Eval Clin Pract2001; 7: 119–123.
ClarkeMJ, StewartLA. Systematic reviews of randomized controlled trials: the need for complete data.J Eval Clin Pract1995; 1: 119–126.
BlackstoneEH. Comparing apples and oranges.J Thorac Cardiovasc Surg2002; 123: 8–15.
D'AgostinoJrRB. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group.Stat Med1998; 17: 2265–2281.
HunterD. First, gather the data.New Engl J Med2006; 354: 329–331.
RubinDB. Estimating causal effects from large data sets using propensity scores.Ann Intern Med1997; 127: 757–763.
NussmeierNA, WheltonAA, BrownMTet al. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery.New Engl J Med2005; 352: 1081–1091.
VandenbrouckeJP. When are observational studies as credible as randomised trials?Lancet2004; 363: 1728–1731.
FeneckR. OPCAB surgery: time for a reappraisal?J Cardiothorac Vasc Anesth2004; 18: 253–255.
EtminanM, Samii EtminanM, SamiiA. Pharmacoepidemiology I: a review of pharmacoepidemiologic study designs.Pharmacotherapy2004; 24: 964–969.
KarkoutiK, BeattieWS, DattiloKMet al. A propensity score case-control comparison of aprotinin and tranexamic acid in high-transfusion-risk cardiac surgery.Transfusion2006; 46: 327–338.
YoungC, HortonR. Putting clinical trials into context.Lancet2005; 366: 107–108.
FergussonD, GlassKC, HuttonB, ShapiroS. Randomized controlled trials of aprotinin in cardiac surgery: could clinical equipoise have stopped the bleeding?Clin Trials2005; 2: 218–229.
SedrakyanA, TreasureT, ElefteriadesJA. Effect of aprotinin on clinical outcomes in coronary artery bypass graft surgery: a systematic review and meta-analysis of randomized clinical trials.J Thorac Cardiovasc Surg2004; 128: 442–448.
SedrakyanA, AtkinsD, TreasureT. The risk of aprotinin: a conflict of evidence.Lancet2006; 367: 1376–1377.
AvornJ. Dangerous deception – hiding the evidence of adverse drug effects.New Engl J Med2006; 355: 2169–2171.
HiattWR. Observational studies of drug safety – aprotinin and the absence of transparency.New Engl J Med2006; 355: 2171–2173.